UroGen Pharma Ltd. Additional Paid in Capital, Common Stock
UroGen Pharma Ltd. (URGN) had Additional Paid in Capital, Common Stock of $865.11 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $865.11M.
- 2026-03-31: Additional Paid in Capital, Common Stock $858.89M.
- 2025-12-31: Additional Paid in Capital, Common Stock $854.09M.
- 2025-09-30: Additional Paid in Capital, Common Stock $817.79M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $865.11M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $858.89M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $854.09M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $817.79M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $806.50M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $803.47M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $797.25M 10-K · filed 2026-03-02 |
| 2024-09-30 | $793.87M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $775.27M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $671.44M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $614.03M 10-K · filed 2025-03-10 |
| 2023-09-30 | $611.39M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $493.11M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $490.74M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $487.79M 10-K · filed 2024-03-14 |
| 2022-09-30 | $485.04M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $481.49M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $478.65M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $475.70M 10-K · filed 2023-03-24 |
| 2021-09-30 | $470.34M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $464.82M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $458.72M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $452.52M 10-K · filed 2022-03-21 |
| 2020-09-30 | $445.95M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $439.00M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $415.89M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $407.99M 10-K · filed 2021-03-18 |
| 2018-12-31 | $212.92M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |